Keywords: Helsinn, Stendhal, Anamorelin, License, Latin America, Cachexia-anorexia, NSCLC
Helsinn grants anamorelin rights to Stendhal for Latin American countries
Article | 29 January 2013
Privately-held Swiss pharmaceutical group Helsinn has granted Latin American specialty company Stendhal exclusive commercialization rights for Mexico, Venezuela, Colombia, Peru, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
